Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
First Claim
Patent Images
1. A method of treating pain in a subject, comprising administering a dosage form to the oral mucosa of a subject, wherein said dosage form comprises:
- from about 5 to about 100 micrograms (mcg) of sufentanil, and a bioadhesive material, wherein;
(i) said bioadhesive material adheres the dosage form to the oral mucosa of said subject during the period of drug delivery;
(ii) said dosage form has a volume of less than 30 microliters or a mass of less than 30 mg; and
(iii) after administration of said dosage form to said subject, said dosage form provides a minimal saliva response and minimal swallowing of sufentanil;
at least 55% of drug delivery of sufentanil occurs via the oral transmucosal route;
said dosage form provides a dose-normalized mean Cmax of 1.59-2.75 pg/mL per mcg dosed;
said dosage form provides a Tmax of from about 19.8 minutes to about 60 minutes; and
said dosage form provides a Tmax with a coefficient of variation of less than 40%.
3 Assignments
0 Petitions
Accused Products
Abstract
Compositions, methods and systems for administration of small volume sufentanil-containing drug dosage forms to the oral mucosa of a subject are disclosed.
322 Citations
15 Claims
-
1. A method of treating pain in a subject, comprising administering a dosage form to the oral mucosa of a subject, wherein said dosage form comprises:
from about 5 to about 100 micrograms (mcg) of sufentanil, and a bioadhesive material, wherein; (i) said bioadhesive material adheres the dosage form to the oral mucosa of said subject during the period of drug delivery; (ii) said dosage form has a volume of less than 30 microliters or a mass of less than 30 mg; and (iii) after administration of said dosage form to said subject, said dosage form provides a minimal saliva response and minimal swallowing of sufentanil; at least 55% of drug delivery of sufentanil occurs via the oral transmucosal route; said dosage form provides a dose-normalized mean Cmax of 1.59-2.75 pg/mL per mcg dosed; said dosage form provides a Tmax of from about 19.8 minutes to about 60 minutes; and said dosage form provides a Tmax with a coefficient of variation of less than 40%. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)
Specification